Progenics
From Verify.Wiki
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics has two commercial products, RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation, which is partnered with Bausch Health Companies, Inc.; and AZEDRA, for the treatment of unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.
 | |
| | |
| Type | Public |
| Founded | 1988 |
| Headquarters | New York, New York |
| Number of employees | 51-200 employees |
Contents
History
Controversies
Top 5 Recent Tweets
| Date | Author | Comment |
|---|---|---|
| April 07, 2023 | urotoday | #TumorBoard Reviewing the Use of PSMA PET in the Care of Patients Who Underwent Fluciclovine for #ProstateCancer… https://t.co/53ba636jbv |
| April 06, 2023 | urotoday | #TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer, Gleason 4+4=8 GG 4 @HJacene @adamkibel_uro… https://t.co/OiGE36oDWX |
| April 04, 2023 | urotoday | #TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer -Gleason 3+4=7, GG 2 (left) Gleason 3+3=6 GG 1 (right)… https://t.co/eufTXMDvyB |
Top 5 Recent News Headlines
Top 5 Lifetime Tweets
Top 5 Lifetime News Headlines
Verification history
1,703 days ago- 1,975 days ago
1,975 days ago- View all verifications
